Heron Therapeutics, Inc. announced the appointment of Steve Davis to Heron's Board of Directors. Mr. Davis has served as Chief Executive Officer and as a director of ACADIA Pharmaceuticals Inc. since 2015 and, previously, as Executive Vice President, Chief Financial Officer and Chief Business Officer from 2014 to 2015. He has more than 25 years of experience in the biopharmaceutical industry. Since 2015, he has served as a director of Bellicum Pharmaceuticals, Inc. From 2012 to 2015, he served as a director of Heron, and, from 2013 to 2014, he served as Executive Vice President, Chief Operating Officer of Heron. Mr. Davis also served as a director of Synageva Biopharma Corp. from 2011 through its acquisition by Alexion Pharmaceuticals, Inc. in 2015. From 2013 to 2014, he served as a director of Furiex Pharmaceuticals, Inc. through its acquisition by Forest Laboratories, Inc. in 2014. He served as Executive Vice President and Chief Operating Officer of Ardea Biosciences, Inc. from 2010 through its acquisition by AstraZeneca PLC in 2012. Previously, he held various positions at Neurogen Corporation, most recently serving as President and Chief Executive Officer. Prior to Neurogen, he practiced as a corporate and securities attorney at a Wall Street law firm and practiced as a certified public accountant at a major accounting firm.